Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Milestone Pharmaceuticals (MIST)
NASDAQ:MIST
RESEARCH TOOLSreports
Holding MIST?
Track your performance easily
MIST Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.12 - $3.52
Previous Close$1.45
Volume204.75K
Average Volume (3M)145.77K
Market Cap
$76.71M
Enterprise Value$47.24M
Total Cash (Recent Filing)$83.25M
Total Debt (Recent Filing)$53.25M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Nov 13, 2024EPS Estimate
-$0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding53,269,565
10 Day Avg. Volume302,072
30 Day Avg. Volume145,772
Standard Deviation0.28
R-Squared0.11
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.93
Price to Sales (P/S)76.71
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.04
Forecast
1Y Price Target
$12.00Price Target Upside727.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Milestone Pharmaceuticals News
PremiumCompany Announcements
Milestone Pharmaceuticals Welcomes New Directors and Auditor
PremiumCompany Announcements
Milestone Pharmaceuticals’ Promising Drug Advancements
PremiumCompany Announcements
Milestone Pharmaceuticals Eyes 2025 for CARDAMYST Launch
PremiumCompany Announcements
Milestone Pharmaceuticals Bolsters Board with New DirectorsBulls Say, Bears Say
Bulls Say
Commercial PreparationsCommercial preparations to support the anticipated launch of CARDAMYST continue apace, increasing the likelihood of success, if approved.
Drug ApprovalThe FDA accepted the New Drug Application for CARDAMYST, placing it on track for potential approval and launch in 2025.
Market OpportunityPSVT represents a large and actionable population in the U.S. with significant potential for expansion.
Bears Say
Financial OutlookThe price target has been adjusted to $9 vs prior $17.
Regulatory IssuesThe FDA requested clarification about time of data recorded for AEs in MIST's Phase 3 trials, though they did not express concerns on the nature/severity of the events.
Treatment EffectivenessCurrent treatment of acute episodes requires emergency hospital visits and hospitalizations, often requiring invasive interventions such as cardiac ablation and heart catheterization, which is burdensome and costly, and both patients and health care providers are dissatisfied with the lack of effective treatment options.
---
Ownership Overview
0.06%
Insiders
0.03% Mutual Funds
0.07% Other Institutional Investors
99.80% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MIST FAQ
What was Milestone Pharmaceuticals’s price range in the past 12 months?
Milestone Pharmaceuticals lowest stock price was $1.12 and its highest was $3.52 in the past 12 months.
What is Milestone Pharmaceuticals’s market cap?
Currently, no data Available
When is Milestone Pharmaceuticals’s upcoming earnings report date?
Milestone Pharmaceuticals’s upcoming earnings report date is Nov 13, 2024 which is in 11 days.
How were Milestone Pharmaceuticals’s earnings last quarter?
Milestone Pharmaceuticals released its earnings results on Aug 08, 2024. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.19 by $0.05.
Is Milestone Pharmaceuticals overvalued?
According to Wall Street analysts Milestone Pharmaceuticals’s price is currently Undervalued.
Does Milestone Pharmaceuticals pay dividends?
Milestone Pharmaceuticals does not currently pay dividends.
What is Milestone Pharmaceuticals’s EPS estimate?
Milestone Pharmaceuticals’s EPS estimate is -$0.16.
How many shares outstanding does Milestone Pharmaceuticals have?
Milestone Pharmaceuticals has 53,269,566 shares outstanding.
What happened to Milestone Pharmaceuticals’s price movement after its last earnings report?
Milestone Pharmaceuticals reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.19. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Milestone Pharmaceuticals?
Among the largest hedge funds holding Milestone Pharmaceuticals’s share is RA Capital Management. It holds Milestone Pharmaceuticals’s shares valued at N/A.
---
Milestone Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (727.59% Upside)
$12.00 (727.59% Upside)
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.35%
12-Months-Change
Fundamentals
Return on Equity
-133.75%
Trailing 12-Months
Asset Growth
-8.03%
Trailing 12-Months
Company Description
Milestone Pharmaceuticals
Milestone Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. It designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.
---
MIST Stock 12 Month Forecast
Average Price Target
$12.00
▲(727.59% Upside)
Technical Analysis
Arcutis Biotherapeutics
―
Blueprint Medicines
―
Karyopharm Therapeutics
―
EyePoint Pharmaceuticals
―
Best Analysts Covering MIST
1 Year
1 Year Success Rate
2/14 ratings generated profit
1 Year Average Return
-34.56%
reiterated a buy rating 12 months ago
Copying Leland Gershell's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -34.56% per trade.
---